Targeted Microbiome Transplant in Atopic Dermatitis

Status Completed

Clinical Trial Summary

The purpose of this study is to examine the safety and effectiveness of a new therapy, commensal lotion containing infection fighting bacteria, on decreasing or eliminating the infection causing bacteria found on the skin of Atopic Dermatitis (AD) patients.

Clinical Trial Description

This study will enroll adult participants, 18-60 years of age, with moderate-to-severe atopic dermatitis (AD) and a positive Staphylococcus aureus (S. aureus) colonized lesion (at least 15 cm^2 in size) on the upper extremities.

Participants who are eligible based on their positive Staph culture results will be randomized to one of two treatments: Targeted Microbiome Transplant Lotion (TMT) or Placebo (2:1 randomization). One lesional site measuring at least 15 cm^2 and one non-lesional site of equal size will be identified on the participant's ventral upper extremities as the target swabbing areas. These sites will be photographed and marked for swabbing for reference at the participant's future visits. Participants will be instructed to apply investigational product with gloved hands to their ventral upper extremities bilaterally from the wrist to the upper humerus, which will include the identified lesional and non-lesional swabbing sites twice a day for 1 week starting on Day 0. Participants will return to clinic on Day 4 for the assessment of adverse events, the collection of skin swabs from the identified target sites, and to obtain additional investigational product and gloves. Participants will complete an additional clinic visit on Day 7 to correspond with the end of their 1 week treatment. During this visit, participants will be assessed for AEs and provide skin swab samples. All unused product and empty packets will be returned during the Day 4 and Day 7 visits. Three additional clinic visits on Days 8, 9, and 11 will be scheduled for additional skin swabs to assess the safety and the stability of the microbiome transplant and time to recurrence of Staph colonization. Participants will be followed through Day 38 to assess for safety and disease status. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03151148
Study type	Interventional
Source	National Institute of Allergy and Infectious Diseases (NIAID)
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	September 28, 2017
Completion date	June 7, 2019

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05456529` - Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis	Phase 3
Completed	`NCT04056130` - A Study of Single and Multiple Ascending Doses of KBL697 in Healthy Subjects	Phase 1
Recruiting	`NCT04173442` - Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy
Completed	`NCT05372653` - A Long-term Trial of OPA-15406 in Infants With Atopic Dermatitis	Phase 3
Completed	`NCT03168113` - Atopic Dermatitis (AD) and Food Allergy	N/A
Terminated	`NCT03389893` - Effect of Dupilumab (Anti-IL4Rα) on the Host-Microbe Interface in Atopic Dermatitis	Phase 4
Recruiting	`NCT04541810` - A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis
Completed	`NCT02357940` - Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema	N/A
Recruiting	`NCT05667623` - To Demonstrate the Superiority of IMP (1% OPA-15406 Ointment) to the Vehicle in Adult Patients With AD	Phase 3
Recruiting	`NCT05650320` - To Demonstrate the Superiority of IMP (0.3% and 1% OPA-15406 Ointment) Versus the Vehicle in Pediatric Patients With AD	Phase 3
Completed	`NCT01979016` - Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)	Phase 2
Withdrawn	`NCT04666675` - A Study of Oral Upadacitinib Tablets to Assess Change in Disease State in Participants Aged 12-75 Years With Moderate to Severe Atopic Dermatitis in Brazil	Phase 3
Active, not recruiting	`NCT05959083` - Real World Study of Oral Upadacitinib Tablets to Assess Adverse Events and Change in Disease Activity in Adolescent and Adult Chinese Participants With Atopic Dermatitis
No longer available	`NCT04159597` - Expanded Access to Upadacitinib

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.